Omalizumab (Xolair) in patients with steroid-resistant asthma: Lessons to be learnt

Philip Thompson, Neil Misso, John Woods

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Very severe asthma and local pulmonary steroid resistance causes major problems for patients, physicians and the health system at large. It usually results in multiple admissions to hospital and high morbidity. Omalizumab was used to treat such patients with success. However, in doing so, it raised a number of issues relating to the best methods of using this treatment in such patients.
Original languageEnglish
Pages (from-to)29-34
JournalRespirology
Volume12
Issue numberSupp. 3
DOIs
Publication statusPublished - 2007

Fingerprint Dive into the research topics of 'Omalizumab (Xolair) in patients with steroid-resistant asthma: Lessons to be learnt'. Together they form a unique fingerprint.

Cite this